HHS issues guidance on ordering commercial COVID-19 monoclonal antibody
The Department of Health and Human Services yesterday released new guidance on ordering, reporting, payment and cost-sharing for the COVID-19 monoclonal antibody therapy bebtelovimab, a treatment option for outpatients at high risk for hospitalization that begins transitioning from HHS to commercial distribution next week. Anticipating depletion of the federal government’s supply, Eli Lilly and Co. is making bebtelovimab available for purchase through AmerisourceBergen.
Related News Articles
Headline
The Food and Drug Administration yesterday announced it has amended the emergency use authorizations for Pfizer’s and Moderna’s COVID-19 vaccines to…
Headline
Pfizer applies for EUA for variant-tailored booster; unveils new efficacy data for youngest children
Pfizer yesterday announced its application for an emergency use authorization for a COVID-19 vaccine booster that is designed to protect against the SARS-CoV-2…
Headline
Novavax today announced the Food and Drug Administration expanded the emergency use authorization for its Adjuvanted (NVX-CoV2373) COVID-19 vaccine. Under…
Headline
The Centers for Medicare & Medicaid Services yesterday released fact sheets summarizing the current status of Medicare COVID-19 blanket waivers and…
Headline
In mid-December, hospitals will transition to reporting COVID-19 data via the Centers for Disease Control and Prevention’s National Healthcare Safety Network,…
Headline
The Food and Drug Administration yesterday advised people who get a negative result from an at-home COVID-19 antigen test to test themselves again after…